Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure

By sjmartinez • December 24, 2022

Talha KM, Fonarow GC, Virani SS, Butler J. Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist Debakey Cardiovasc J. 2022 Dec 6;18(5):40-53. doi: 10.14797/mdcvj.1155. PMID: 36561085; PMCID: PMC9733124.

Tags: Cardiology/Epi, cardiovascular disease, glucagon-like peptide 1 receptor agonist, heart failure, prevention, Publications, sodium-glucose cotransporter-2 inhibitor

Artificial-intelligence-assisted CCTA quantifies sex differences in coronary atherosclerotic burden at low atheroma volumes

D'Costa Z, Karlsberg RP, Cho GW. Artificial-intelligence-assisted CCTA quantifies sex differences in coronary atherosclerotic burden at low atheroma volumes. Int J Cardiol Heart Vasc. 2025[...]

Genetic and sex-specific regulation of mitochondrial function in gonadal and inguinal adipose tissue

Kaminska D, Pan C, Vergnes L, Ro A, Ulaganathan G, Lusis AJ. Genetic and sex-specific regulation of mitochondrial function in gonadal and inguinal adipose tissue.[...]

A call for transparency, improved reporting, and interpretation of trials using surrogate end points in cardiac electrophysiology

Tereshchenko LG, Manyara AM, Ciani O, Sodeke SO, Bradford CN, Santangeli P, Kapadia SR, Wazni O, Narayan SM, Chugh SS, Bilchick K, Huizar JF, Vaseghi[...]